Sekisui Chemical Of Japan To Increase Overseas Diagnostic Agent Sales
This article was originally published in PharmAsia News
Executive Summary
Sekisui Chemical plans to increase overseas diagnostic agent sales from its current 20 percent to 30 percent in 2013. Last year, the top Japanese diagnostic maker acquired U.S. companies Xenotech and American Diagnostics. Sekisui plans to expand Xenotech's pharmacokinetics business and ADI's DVV line of diagnostic tests, which detect specific antibodies related to conditions associated with lupus anticoagulants. Five core areas identified by the company are: LDL/HDL testing agents, anticoagulants, diabetes, infection and advanced technology. (Click here for more - Japanese Language